An Act to amend and reenact ยงยง 38.2-3407.15:5 and 38.2-3418.10 of the Code of Virginia, relating to health insurance; cost-sharing payments for insulin and diabetes equipment and supplies; limit.
Impact
The enactment of HB1214 will have a significant impact on state laws governing health insurance and diabetes treatment. By establishing a maximum cost-sharing requirement, the bill is expected to alleviate some of the financial strain on individuals with diabetes, who may struggle with the cost of ongoing insulin therapy and required medical equipment. This legislative change is likely to enhance accessibility for patients, ultimately leading to better health outcomes as more individuals may adhere to prescribed treatments without the deterrent of high out-of-pocket costs.
Summary
House Bill 1214 is designed to limit cost-sharing payments for prescription insulin drugs and diabetes equipment and supplies in Virginia. Under this bill, every health plan offered by carriers is required to cap the cost a covered person pays for prescription insulin drugs at $35 for a 30-day supply, regardless of the amount or type of insulin prescribed. Additionally, the bill mandates that coverage for diabetes includes benefits for necessary equipment and supplies, such as glucose meters and continuous glucose monitors, thereby aiming to improve access and reduce financial burdens for individuals requiring diabetes care.
Sentiment
The overall sentiment regarding HB1214 appears to be positive, with broad support for its provisions aimed at reducing insulin expenses. Supporters argue that limiting cost-sharing is a necessary step towards making diabetes management more affordable and equitable, especially in a time when rising healthcare costs have become a pressing issue. However, there may also be some concerns about how insurance companies will adapt to these requirements and ensure compliance, particularly regarding their reimbursement structures and pricing strategies.
Contention
Notable points of contention about HB1214 may arise concerning the implementation and sustainability of the mandated cost-sharing limits. While the intention to improve healthcare affordability is widely shared, some stakeholders, including insurance companies, may express concerns over the potential financial implications of such regulations on their business models. Additionally, there may be discussions regarding the adequacy of coverage provided and how it aligns with existing healthcare frameworks, and if they might inadvertently create barriers in the form of reduced availability of certain services.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.